A Multicenter, Fixed-Dose, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of AR19 (Amphetamine Sulfate) in Adult Subjects (Ages 18-55) With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs Amfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Arbor Pharmaceuticals
- 19 Feb 2019 Planned number of patients changed from 400 to 312.
- 19 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 17 Sep 2018 Status changed from not yet recruiting to recruiting.